Study of Everolimus (RAD001) in Combination With Lenalidomide

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 28% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-11-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lenalidomidedlcancertherapyable to
  Phrases that lowered it: subjectstopicalimpairmentadministrationhepatic
• Sponsor's past termination rate: 19.6% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 45.1% (raises risk) · Drug's FDA history
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 66 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 89.0% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) NCT01183663 · started 2010 · scored riskier than 99% of active trials completed
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma NCT02898259 · started 2017 · scored riskier than 86% of active trials terminated
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma NCT01564537 · started 2012 · scored riskier than 26% of active trials completed
• Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma NCT02075021 · started 2014 · scored riskier than 74% of active trials terminated
• Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer NCT02018523 · started 2014 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.